Digital pathology software developer Proscia has formed a new strategic partnership with pathology artificial intelligence (AI) firm Visiopharm to integrate each firm's software to improve clinical decision making for colon and breast cancer care.
Under the deal, Visiopharm’s clinical AI application suite will be integrated into Proscia’s Concentriq Dx software platform. As a result, Concentriq Dx users will be able to utilize Visiopharm’s AI applications, such as breast immunohistochemistry (IHC) markers, breast metastasis detection, and colon metastasis detection, directly in their routine workflow, according to the vendors. The two firms had previously collaborated in the research market.
